Skip to main content

Table 1 FDA Adverse Event Reporting System analysis case demographics

From: A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Characteristics

n (%)

Total

90,740

Age

63 (53–70)

Sex

 Male

41,162 (45.4%)

 Female

49,578 (54.6%)

Weight (kg)

73.5 (59.8–84.0)

Cardiac Adverse Events

8300 (9.1%)

 Myocarditis

345 (0.4%)

 Pericarditis

143 (0.2%)

 Heart Failure

1706 (1.9%)

 Myocardial Infarction

1594 (1.8%)

 Arrhythmias

3858 (4.3%)

 Coronary Artery Disease

654 (0.7%)

Anti-inflammatory medication use

18,797 (20.7%)

Cardioprotective medication use

23,372 (25.8%)

Treatment groups

 anti-PD-(L)1

18,536 (20.4%)

 anti-CTLA4

1855 (2%)

 combination immunotherapy

4442 (4.9%)

 Chemotherapy

65,907 (72.6%)

  1. PD-(L)1 = Programmed cell death protein -1 and Programmed death ligand -1 therapies; CTLA = cytotoxic T-lymphocyte-associated protein 4